Abstract
Amicrobial pustulosis of the folds (APF) is a recently described entity characterized by relapsing pustular lesions predominantly involving the cutaneous flexures and scalp. This disease typically occurs in association with systemic lupus erythematosus and a variety of other autoimmune diseases. We here describe an APF-like pustular eruption predominantly affecting the scalp, face and trunk, occurring during long-term infliximab treatment for Crohn's disease. Immunohistochemical staining of skin biopsy specimens for myxovirus resistance protein A, a marker for type 1 interferon-inducible proteins, showed increased staining in the epidermis and dermal mononuclear inflammatory infiltrate. Our observation further extends the spectrum of cutaneous adverse reactions potentially related to anti-tumor necrosis factor-α, the clinical context in which APF can occur as well as its clinical presentations.
Copyright © 2011 S. Karger AG, Basel.
MeSH terms
-
Acute Generalized Exanthematous Pustulosis / chemically induced*
-
Acute Generalized Exanthematous Pustulosis / drug therapy
-
Acute Generalized Exanthematous Pustulosis / pathology
-
Amoxicillin-Potassium Clavulanate Combination / therapeutic use
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Crohn Disease / drug therapy*
-
Dermatologic Agents / therapeutic use
-
Female
-
GTP-Binding Proteins / metabolism
-
Gastrointestinal Agents / adverse effects*
-
Gastrointestinal Agents / therapeutic use
-
Humans
-
Infliximab
-
Myxovirus Resistance Proteins
-
Neutrophils / pathology
-
Prednisolone / therapeutic use
-
Severity of Illness Index
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Young Adult
Substances
-
Antibodies, Monoclonal
-
Dermatologic Agents
-
Gastrointestinal Agents
-
Myxovirus Resistance Proteins
-
Tumor Necrosis Factor-alpha
-
Amoxicillin-Potassium Clavulanate Combination
-
Prednisolone
-
Infliximab
-
GTP-Binding Proteins